Wednesday, March 01, 2006
SansRosa, now aka COL-118
From a Collagenex press release:
"CollaGenex is also developing COL-118, utilizing the technology acquired in the SansRosa acquisition, as a preclinical topical compound for the treatment of redness associated with rosacea and other skin disorders. "
Under the 2006 financial guidance section:
"Research and development expenses: R&D expense is expected to be approximately $17 million and is expected to be invested primarily in the ongoing Phase II dose-ranging studies for incyclinide for the treatment of acne, various Phase II and Phase IV clinical trials for Oracea, continuing formulation development work for Restoraderm and formulation development work for COL-118, utilizing the technology acquired in the acquisition of SansRosa in 2005. "
So, still at the formulation stage and no mention of any clinical trials as of yet.
Previous SansRosa news:
Our first post on SansRosa Transcript of interview with founder Windhover SansRosa report snippets SansRosa patent details Collagenex purchases SansRosa
"CollaGenex is also developing COL-118, utilizing the technology acquired in the SansRosa acquisition, as a preclinical topical compound for the treatment of redness associated with rosacea and other skin disorders. "
Under the 2006 financial guidance section:
"Research and development expenses: R&D expense is expected to be approximately $17 million and is expected to be invested primarily in the ongoing Phase II dose-ranging studies for incyclinide for the treatment of acne, various Phase II and Phase IV clinical trials for Oracea, continuing formulation development work for Restoraderm and formulation development work for COL-118, utilizing the technology acquired in the acquisition of SansRosa in 2005. "
So, still at the formulation stage and no mention of any clinical trials as of yet.
Previous SansRosa news:
